Sanofi - Regeneron's Libtayo/Chemo Treatment Improves Overall Survival First-Line Lung Cancer

by Vandana Singh, Benzinga Editor

August 5, 2021 9:18 AM | 1 min read | Make a Comment

The Phase 3 trial of Sanofi SA SNY and Regeneron Pharmaceuticals Inc's REGN Libtayo in combination with platinum-doublet chemotherapy was stopped early after meeting its overall survival (OS) primary endpoint in patients with advanced non-small-cell lung cancer (NSCLC).
These data are planned to form the basis of regulatory submissions in the U.S. and European Union.
In this top-line initial analysis of 466 patients, combining Libtayo with chemotherapy reduced the risk of death by 29% compared to chemotherapy alone.
Median OS was 22 months for Libtayo/chemo combo and 13 months for chemotherapy alone.
No new Libtayo safety signals were identified.
Price Action: REGN shares are up 2.45 at $594.75, and SNY stock is up 1.1% at $50.45 during the premarket session on the last check Thursday.

Posted In: Biotech News Health Care Movers Trading Ideas General Briefs Non-Small Cell Lung Cancer

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.